<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20231018203714
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20231018203714" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 19 Oct 2023 00:37:15 +0000</lastbuilddate>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Errors in Abstract and Supplement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37851467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 18. doi: 10.1001/jamacardio.2023.4008. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37851467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37851467</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4008>10.1001/jamacardio.2023.4008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37851467</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Errors in Abstract and Supplement</dc:title>
<dc:identifier>pmid:37851467</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4008</dc:identifier>
</item>
<item>
<title>Deep Learning to Identify Undiagnosed AF Using ECGs in Sinus Rhythm-Should We Rewire Our Models?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37851465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 18. doi: 10.1001/jamacardio.2023.3710. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37851465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37851465</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3710>10.1001/jamacardio.2023.3710</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37851465</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Mark S Brahier</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Deep Learning to Identify Undiagnosed AF Using ECGs in Sinus Rhythm-Should We Rewire Our Models?</dc:title>
<dc:identifier>pmid:37851465</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3710</dc:identifier>
</item>
<item>
<title>Lead Extraction and Mortality Among Patients With Cardiac Implanted Electronic Device Infection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37851461/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this study, a minority of patients with CIED infection underwent extraction. Extraction was associated with a lower risk of death compared with no extraction. The findings suggest a need to improve adherence to guideline-directed care among patients with CIED infection.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 18. doi: 10.1001/jamacardio.2023.3379. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Complete hardware removal is a class I recommendation for cardiovascular implantable electronic device (CIED) infection, but practice patterns and outcomes remain unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To quantify the number of Medicare patients with CIED infections who underwent implantation from 2006 to 2019 and lead extraction from 2007 to 2019 to analyze the outcomes in these patients in a nationwide clinical practice cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study included fee-for-service Medicare Part D beneficiaries from January 1, 2006, to December 31, 2019, who had a de novo CIED implantation and a CIED infection more than 1 year after implantation. Data were analyzed from January 1, 2005, to December 31, 2019.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: A CIED infection, defined as (1) endocarditis or infection of a device implant and (2) documented antibiotic therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes of interest were device infection, device extraction, and all-cause mortality. Time-varying multivariable Cox proportional hazards regression models were used to evaluate the association between extraction and survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1 065 549 patients (median age, 78.0 years [IQR, 72.0-84.0 years]; 50.9% male), mean (SD) follow-up was 4.6 (2.9) years after implantation. There were 11 304 patients (1.1%) with CIED infection (median age, 75.0 years [IQR, 67.0-82.0 years]); 60.1% were male, and 7724 (68.3%) had diabetes. A total of 2102 patients with CIED infection (18.6%) underwent extraction within 30 days of diagnosis. Infection occurred a mean (SD) of 3.7 (2.4) years after implantation, and 1-year survival was 68.3%. There was evidence of highly selective treatment, as most patients did not have extraction within 30 days of diagnosed infection (9202 [81.4%]), while 1511 (13.4%) had extraction within 6 days of diagnosis and 591 (5.2%) had extraction between days 7 and 30. Any extraction was associated with lower mortality compared with no extraction (adjusted hazard ratio [AHR], 0.82; 95% CI, 0.74-0.90; P &lt; .001). Extraction within 6 days was associated with even lower risk of mortality (AHR, 0.69; 95% CI, 0.61-0.78; P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, a minority of patients with CIED infection underwent extraction. Extraction was associated with a lower risk of death compared with no extraction. The findings suggest a need to improve adherence to guideline-directed care among patients with CIED infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37851461/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37851461</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3379>10.1001/jamacardio.2023.3379</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37851461</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Sean D Pokorney</dc:creator>
<dc:creator>Lindsay Zepel</dc:creator>
<dc:creator>Melissa A Greiner</dc:creator>
<dc:creator>Vance G Fowler</dc:creator>
<dc:creator>Eric Black-Maier</dc:creator>
<dc:creator>Robert K Lewis</dc:creator>
<dc:creator>Donald D Hegland</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Laurence M Epstein</dc:creator>
<dc:creator>Roger G Carrillo</dc:creator>
<dc:creator>Bruce L Wilkoff</dc:creator>
<dc:creator>Chantelle Hardy</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Lead Extraction and Mortality Among Patients With Cardiac Implanted Electronic Device Infection</dc:title>
<dc:identifier>pmid:37851461</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3379</dc:identifier>
</item>
<item>
<title>Explanation of Error in "Effect of Brief Counseling by Allied Health Professionals on Step Count of People With Peripheral Artery Disease: A Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37851460/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 18. doi: 10.1001/jamacardio.2023.3713. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37851460/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37851460</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3713>10.1001/jamacardio.2023.3713</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37851460</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonathan Golledge</dc:creator>
<dc:creator>Alkira Venn</dc:creator>
<dc:creator>Joseph V Moxon</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Explanation of Error in "Effect of Brief Counseling by Allied Health Professionals on Step Count of People With Peripheral Artery Disease: A Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:37851460</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3713</dc:identifier>
</item>
<item>
<title>An Elderly Woman With Ventricular Tachycardia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37851453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 18. doi: 10.1001/jamacardio.2023.3580. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37851453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37851453</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3580>10.1001/jamacardio.2023.3580</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37851453</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Amr Idris</dc:creator>
<dc:creator>João L Cavalcante</dc:creator>
<dc:creator>David Lin</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>An Elderly Woman With Ventricular Tachycardia</dc:title>
<dc:identifier>pmid:37851453</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3580</dc:identifier>
</item>
<item>
<title>Deep Learning of Electrocardiograms in Sinus Rhythm From US Veterans to Predict Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37851434/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Deep learning of outpatient sinus rhythm ECGs predicted AF within 31 days in populations with diverse demographics and comorbidities. Similar models could be used in future AF screening efforts to reduce adverse complications associated with this disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 18. doi: 10.1001/jamacardio.2023.3701. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Early detection of atrial fibrillation (AF) may help prevent adverse cardiovascular events such as stroke. Deep learning applied to electrocardiograms (ECGs) has been successfully used for early identification of several cardiovascular diseases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether deep learning models applied to outpatient ECGs in sinus rhythm can predict AF in a large and diverse patient population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This prognostic study was performed on ECGs acquired from January 1, 1987, to December 31, 2022, at 6 US Veterans Affairs (VA) hospital networks and 1 large non-VA academic medical center. Participants included all outpatients with 12-lead ECGs in sinus rhythm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: A convolutional neural network using 12-lead ECGs from 2 US VA hospital networks was trained to predict the presence of AF within 31 days of sinus rhythm ECGs. The model was tested on ECGs held out from training at the 2 VA networks as well as 4 additional VA networks and 1 large non-VA academic medical center.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 907 858 ECGs from patients across 6 VA sites were included in the analysis. These patients had a mean (SD) age of 62.4 (13.5) years, 6.4% were female, and 93.6% were male, with a mean (SD) CHA2DS2-VASc (congestive heart failure, hypertension, age, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age, sex category) score of 1.9 (1.6). A total of 0.2% were American Indian or Alaska Native, 2.7% were Asian, 10.7% were Black, 4.6% were Latinx, 0.7% were Native Hawaiian or Other Pacific Islander, 62.4% were White, 0.4% were of other race or ethnicity (which is not broken down into subcategories in the VA data set), and 18.4% were of unknown race or ethnicity. At the non-VA academic medical center (72 483 ECGs), the mean (SD) age was 59.5 (15.4) years and 52.5% were female, with a mean (SD) CHA2DS2-VASc score of 1.6 (1.4). A total of 0.1% were American Indian or Alaska Native, 7.9% were Asian, 9.4% were Black, 2.9% were Latinx, 0.03% were Native Hawaiian or Other Pacific Islander, 74.8% were White, 0.1% were of other race or ethnicity, and 4.7% were of unknown race or ethnicity. A deep learning model predicted the presence of AF within 31 days of a sinus rhythm ECG on held-out test ECGs at VA sites with an area under the receiver operating characteristic curve (AUROC) of 0.86 (95% CI, 0.85-0.86), accuracy of 0.78 (95% CI, 0.77-0.78), and F1 score of 0.30 (95% CI, 0.30-0.31). At the non-VA site, AUROC was 0.93 (95% CI, 0.93-0.94); accuracy, 0.87 (95% CI, 0.86-0.88); and F1 score, 0.46 (95% CI, 0.44-0.48). The model was well calibrated, with a Brier score of 0.02 across all sites. Among individuals deemed high risk by deep learning, the number needed to screen to detect a positive case of AF was 2.47 individuals for a testing sensitivity of 25% and 11.48 for 75%. Model performance was similar in patients who were Black, female, or younger than 65 years or who had CHA2DS2-VASc scores of 2 or greater.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Deep learning of outpatient sinus rhythm ECGs predicted AF within 31 days in populations with diverse demographics and comorbidities. Similar models could be used in future AF screening efforts to reduce adverse complications associated with this disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37851434/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37851434</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3701>10.1001/jamacardio.2023.3701</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37851434</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Neal Yuan</dc:creator>
<dc:creator>Grant Duffy</dc:creator>
<dc:creator>Sanket S Dhruva</dc:creator>
<dc:creator>Adam Oesterle</dc:creator>
<dc:creator>Cara N Pellegrini</dc:creator>
<dc:creator>John Theurer</dc:creator>
<dc:creator>Marzieh Vali</dc:creator>
<dc:creator>Paul A Heidenreich</dc:creator>
<dc:creator>Salomeh Keyhani</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Deep Learning of Electrocardiograms in Sinus Rhythm From US Veterans to Predict Atrial Fibrillation</dc:title>
<dc:identifier>pmid:37851434</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3701</dc:identifier>
</item>
<item>
<title>Acute heart failure: current pharmacological treatment and perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850661/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>Acute heart failure (AHF) represents the most frequent cause of unplanned hospital admission in patients older than 65 years. Symptoms and clinical signs of AHF (e.g. dyspnoea, orthopnoea, oedema, jugular vein distension, and variation of body weight) are mostly related to systemic venous congestion secondary to various mechanisms including extracellular fluids, increased ventricular filling pressures, and/or auto-transfusion of blood from the splanchnic into the pulmonary circulation. Thus, the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 18:ehad617. doi: 10.1093/eurheartj/ehad617. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Acute heart failure (AHF) represents the most frequent cause of unplanned hospital admission in patients older than 65 years. Symptoms and clinical signs of AHF (e.g. dyspnoea, orthopnoea, oedema, jugular vein distension, and variation of body weight) are mostly related to systemic venous congestion secondary to various mechanisms including extracellular fluids, increased ventricular filling pressures, and/or auto-transfusion of blood from the splanchnic into the pulmonary circulation. Thus, the initial management of AHF patients should be mostly based on decongestive therapies on admission followed, before discharge, by rapid implementation of guideline-directed oral medical therapies for heart failure. The therapeutic management of AHF requires the identification and rapid diagnosis of the disease, the diagnosis of the cause (or triggering factor), the evaluation of severity, the presence of comorbidities, and, finally, the initiation of a rapid treatment. The most recent guidelines from ESC and ACC/AHA/HFSA have provided updated recommendations on AHF management. Recommended pharmacological treatment for AHF includes diuretic therapy aiming to relieve congestion and achieve optimal fluid status, early and rapid initiation of oral therapies before discharge combined with a close follow-up. Non-pharmacological AHF management requires risk stratification in the emergency department and non-invasive ventilation in case of respiratory failure. Vasodilators should be considered as initial therapy in AHF precipitated by hypertension. On the background of recent large randomized clinical trials and international guidelines, this state-of-the-art review describes current pharmacological treatments and potential directions for future research in AHF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850661</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad617>10.1093/eurheartj/ehad617</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850661</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Benjamin Deniau</dc:creator>
<dc:creator>Maria Rosa Costanzo</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Ayu Asakage</dc:creator>
<dc:creator>Wilfried Mullens</dc:creator>
<dc:creator>Alexandre Mebazaa</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acute heart failure: current pharmacological treatment and perspectives</dc:title>
<dc:identifier>pmid:37850661</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad617</dc:identifier>
</item>
<item>
<title>The first European Union approval of a new medicine to treat cardiovascular diseases in 2023: why is it important to collaborate with the European Medicines Agency?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 18:ehad426. doi: 10.1093/eurheartj/ehad426. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850604</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad426>10.1093/eurheartj/ehad426</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850604</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Piotr Szymański</dc:creator>
<dc:creator>Eva Irene Bossano Prescott</dc:creator>
<dc:creator>Franz Weidinger</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The first European Union approval of a new medicine to treat cardiovascular diseases in 2023: why is it important to collaborate with the European Medicines Agency?</dc:title>
<dc:identifier>pmid:37850604</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad426</dc:identifier>
</item>
<item>
<title>A transcontinental voyage of discovery in advancing our understanding of cardiac genetics: interview with Roger Foo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850522/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 18:ehad681. doi: 10.1093/eurheartj/ehad681. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850522/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850522</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad681>10.1093/eurheartj/ehad681</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850522</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A transcontinental voyage of discovery in advancing our understanding of cardiac genetics: interview with Roger Foo</dc:title>
<dc:identifier>pmid:37850522</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad681</dc:identifier>
</item>
<item>
<title>Prognostic value of intravascular ultrasound early after heart transplantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 18:ehad648. doi: 10.1093/eurheartj/ehad648. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850514</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad648>10.1093/eurheartj/ehad648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850514</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Satish Arora</dc:creator>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:creator>Ole Geir Solberg</dc:creator>
<dc:creator>Kari Nytrøen</dc:creator>
<dc:creator>Lars Aaberge</dc:creator>
<dc:creator>Kozo Okada</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>Yasuhiro Honda</dc:creator>
<dc:creator>Kiran K Khush</dc:creator>
<dc:creator>Oscar Angeras</dc:creator>
<dc:creator>Kristjan Karason</dc:creator>
<dc:creator>Lars Gullestad</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prognostic value of intravascular ultrasound early after heart transplantation</dc:title>
<dc:identifier>pmid:37850514</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad648</dc:identifier>
</item>
<item>
<title>Where there is smoke there is risk: is there an irreversible threshold?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850511/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 18:ehad685. doi: 10.1093/eurheartj/ehad685. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850511</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad685>10.1093/eurheartj/ehad685</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850511</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Xavier Garcia-Moll</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Where there is smoke there is risk: is there an irreversible threshold?</dc:title>
<dc:identifier>pmid:37850511</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad685</dc:identifier>
</item>
<item>
<title>Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850397/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Rivaroxaban added to aspirin or dual antiplatelet therapy after LER for peripheral artery disease reduces ischemic risk and increases major bleeding without an increased risk of intracranial or fatal bleeding. These benefits are consistent in those treated with endovascular and surgical approaches with significant benefits for major adverse limb events. These data support the use of rivaroxaban in addition to aspirin or dual antiplatelet therapy after endovascular intervention for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063806. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Rivaroxaban plus aspirin compared with aspirin alone reduced major cardiac and ischemic limb events after lower extremity revascularization (LER) in the VOYAGER PAD (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) trial. The effect has not been described in patients undergoing endovascular LER.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The VOYAGER PAD trial randomized 6564 patients with symptomatic peripheral artery disease to a double-blinded to treatment with 2.5 mg of rivaroxaban BID or matching placebo and 100 mg of aspirin daily. The primary efficacy outcome was a composite of acute limb ischemia, major amputation of a vascular pathogenesis, myocardial infarction, ischemic stroke, or cardiovascular death. The principal safety end point was Thrombolysis in Myocardial Infarction major bleeding. A prespecified subgroup of patients who underwent endovascular revascularization was included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Endovascular LER occurred in 4379 (66.7%) patients and surgical LER in 2185 (33.3%). Over a 3-year follow-up, rivaroxaban reduced the risk of the primary outcome by 15% (hazard ratio [HR], 0.85 [95% CI, 0.76-0.96]) with an absolute risk reduction of 0.92% at 6 months and 1.04% at 3 years and a consistent benefit in those receiving endovascular (HR, 0.89 [95% CI, 0.76-1.03]) or surgical LER (HR, 0.81 [95% CI, 0.67-0.98]; <i>P</i> interaction=0.43). For endovascular-treated patients, rivaroxaban reduced the risk of acute limb ischemia or major amputation of a vascular pathogenesis by 30% (HR, 0.70 [95% CI, 0.54-0.90]; <i>P</i>=0.005) with an absolute risk reduction of 1.0% at 6 months and 2.0% at 3 years compared with aspirin alone. Among endovascular-treated patients, the median duration of concomitant dual antiplatelet therapy with clopidogrel treatment was 31 days (interquartile range, 30-58). There was a consistent benefit for rivaroxaban regardless of background clopidogrel. Thrombolysis in Myocardial Infarction major bleeding was significantly higher for the rivaroxaban and aspirin group for the endovascular cohort (HR, 1.66 [95% CI, 1.06-2.59]) with an absolute risk increase of 0.9% at 3 years with no increase in intracranial or fatal bleeding observed (HR, 0.86 [95% CI, 0.40-1.87]; <i>P</i>=0.71). Mortality with rivaroxaban was higher in the endovascular-treated patients (HR, 1.24 [95% CI, 1.02-1.52]), although this finding was isolated to specific regions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Rivaroxaban added to aspirin or dual antiplatelet therapy after LER for peripheral artery disease reduces ischemic risk and increases major bleeding without an increased risk of intracranial or fatal bleeding. These benefits are consistent in those treated with endovascular and surgical approaches with significant benefits for major adverse limb events. These data support the use of rivaroxaban in addition to aspirin or dual antiplatelet therapy after endovascular intervention for symptomatic peripheral artery disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850397/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850397</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063806>10.1161/CIRCULATIONAHA.122.063806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850397</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Rymer</dc:creator>
<dc:creator>Sonia S Anand</dc:creator>
<dc:creator>E Sebastian Debus</dc:creator>
<dc:creator>Lloyd P Haskell</dc:creator>
<dc:creator>Connie N Hess</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Eva Muehlhofer</dc:creator>
<dc:creator>Scott D Berkowitz</dc:creator>
<dc:creator>Rupert M Bauersachs</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD</dc:title>
<dc:identifier>pmid:37850397</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063806</dc:identifier>
</item>
<item>
<title>Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850394/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: R-enantiomer carvedilol attenuates hyperdynamic contraction, suppresses arrhythmia, and at the same time, improves cardiac output without lowering heart rate by dual blockade of α(1)-adrenergic receptor and RyR2 in mouse and human models of HCM. This combination of therapeutic effects is unique among current therapeutic options for HCM and may particularly benefit patients without LV outflow tract obstruction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.123.065017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypercontractility and arrhythmia are key pathophysiologic features of hypertrophic cardiomyopathy (HCM), the most common inherited heart disease. β-Adrenergic receptor antagonists (β-blockers) are the first-line therapy for HCM. However, β-blockers commonly selected for this disease are often poorly tolerated in patients, where heart-rate reduction and noncardiac effects can lead to reduced cardiac output and fatigue. Mavacamten, myosin ATPase inhibitor recently approved by the US Food and Drug Administration, has demonstrated the ability to ameliorate hypercontractility without lowering heart rate, but its benefits are so far limited to patients with left ventricular (LV) outflow tract obstruction, and its effect on arrhythmia is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We screened 21 β-blockers for their impact on myocyte contractility and evaluated the antiarrhythmic properties of the most promising drug in a ventricular myocyte arrhythmia model. We then examined its in vivo effect on LV function by hemodynamic pressure-volume loop analysis. The efficacy of the drug was tested in vitro and in vivo compared with current therapeutic options (metoprolol, verapamil, and mavacamten) for HCM in an established mouse model of HCM (<i>Myh6</i><sup>R403Q</sup><sup>/+</sup> [myosin heavy chain 6]) and iPSC cardiomyocytes derived from patients with HCM (<i>MYH7</i><sup>R403Q/+</sup>) [myosin heavy chain 7]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified that carvedilol, a β-blocker not commonly used in HCM, suppresses contractile function and arrhythmia by inhibiting RyR2 (ryanodine receptor type 2). Unlike metoprolol (a β<sub>1</sub>-blocker), carvedilol markedly reduced LV contractility through RyR2 inhibition, while maintaining stroke volume through α<sub>1</sub>-adrenergic receptor inhibition in vivo. Clinically available carvedilol is a racemic mixture, and the R-enantiomer, devoid of β-blocking effect, retains the ability to inhibit both α<sub>1</sub>-receptor and RyR2, thereby suppressing contractile function and arrhythmias without lowering heart rate and cardiac output. In <i>Myh6</i><sup>R403Q/+</sup> mice, R-carvedilol normalized hyperdynamic contraction, suppressed arrhythmia, and increased cardiac output better than metoprolol, verapamil, and mavacamten. The ability of R-carvedilol to suppress contractile function was well retained in <i>MYH7</i><sup>R403Q/+</sup> induced pluripotent stem cell cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: R-enantiomer carvedilol attenuates hyperdynamic contraction, suppresses arrhythmia, and at the same time, improves cardiac output without lowering heart rate by dual blockade of α<sub>1</sub>-adrenergic receptor and RyR2 in mouse and human models of HCM. This combination of therapeutic effects is unique among current therapeutic options for HCM and may particularly benefit patients without LV outflow tract obstruction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850394/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850394</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065017>10.1161/CIRCULATIONAHA.123.065017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850394</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Kinya Seo</dc:creator>
<dc:creator>Yuta Yamamoto</dc:creator>
<dc:creator>Anna Kirillova</dc:creator>
<dc:creator>Masataka Kawana</dc:creator>
<dc:creator>Sunil Yadav</dc:creator>
<dc:creator>Yong Huang</dc:creator>
<dc:creator>Qianru Wang</dc:creator>
<dc:creator>Kerry V Lane</dc:creator>
<dc:creator>Beth L Pruitt</dc:creator>
<dc:creator>Marco V Perez</dc:creator>
<dc:creator>Daniel Bernstein</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:creator>Matthew T Wheeler</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Euan A Ashley</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol</dc:title>
<dc:identifier>pmid:37850394</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065017</dc:identifier>
</item>
<item>
<title>Cellular Heterogeneity of Activated Primary Human Macrophages and Associated Drug-Gene Networks: From Biology to Precision Therapeutics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850387/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We characterized 2 clusters of macrophages in atherosclerosis and combined our cellular data with a cell-signature drug library to identify a novel compound that targets a subset of macrophages in atherosclerosis. Our approach is a precision medicine strategy to identify new drugs that target atherosclerosis and other inflammatory diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.123.064794. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Interferon-γ (IFNγ) signaling plays a complex role in atherogenesis. IFNγ stimulation of macrophages permits in vitro exploration of proinflammatory mechanisms and the development of novel immune therapies. We hypothesized that the study of macrophage subpopulations could lead to anti-inflammatory interventions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Primary human macrophages activated by IFNγ (M[IFNγ]) underwent analyses by single-cell RNA sequencing, time-course cell-cluster proteomics, metabolite consumption, immunoassays, and functional tests (phagocytic, efferocytotic, and chemotactic). RNA-sequencing data were analyzed in LINCS (Library of Integrated Network-Based Cellular Signatures) to identify compounds targeting M(IFNγ) subpopulations. The effect of compound BI-2536 was tested in human macrophages in vitro and in a murine model of atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Single-cell RNA sequencing identified 2 major clusters in M(IFNγ): inflammatory (M[IFNγ]<sup><i>i</i></sup>) and phagocytic (M[IFNγ]<sup><i>p</i></sup>). M(IFNγ)<sup><i>i</i></sup> had elevated expression of inflammatory chemokines and higher amino acid consumption compared with M(IFNγ)<sup><i>p</i></sup>. M(IFNγ)<sup><i>p</i></sup> were more phagocytotic and chemotactic with higher Krebs cycle activity and less glycolysis than M(IFNγ)<sup><i>i</i></sup>. Human carotid atherosclerotic plaques contained 2 such macrophage clusters. Bioinformatic LINCS analysis using our RNA-sequencing data identified BI-2536 as a potential compound to decrease the M(IFNγ)<sup><i>i</i></sup> subpopulation. BI-2536 in vitro decreased inflammatory chemokine expression and secretion in M(IFNγ) by shrinking the M(IFNγ)<sup><i>i</i></sup> subpopulation while expanding the M(IFNγ)<sup><i>p</i></sup> subpopulation. BI-2536 in vivo shifted the phenotype of macrophages, modulated inflammation, and decreased atherosclerosis and calcification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We characterized 2 clusters of macrophages in atherosclerosis and combined our cellular data with a cell-signature drug library to identify a novel compound that targets a subset of macrophages in atherosclerosis. Our approach is a precision medicine strategy to identify new drugs that target atherosclerosis and other inflammatory diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850387</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064794>10.1161/CIRCULATIONAHA.123.064794</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850387</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Julius L Decano</dc:creator>
<dc:creator>Enrico Maiorino</dc:creator>
<dc:creator>Joan T Matamalas</dc:creator>
<dc:creator>Sarvesh Chelvanambi</dc:creator>
<dc:creator>Bart M Tiemeijer</dc:creator>
<dc:creator>Yoshihiro Yanagihara</dc:creator>
<dc:creator>Shin Mukai</dc:creator>
<dc:creator>Prabhash Kumar Jha</dc:creator>
<dc:creator>Diego V S Pestana</dc:creator>
<dc:creator>Edwin D'Souza</dc:creator>
<dc:creator>Mary Whelan</dc:creator>
<dc:creator>Rile Ge</dc:creator>
<dc:creator>Takaharu Asano</dc:creator>
<dc:creator>Amitabh Sharma</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Sasha A Singh</dc:creator>
<dc:creator>Elena Aikawa</dc:creator>
<dc:creator>Masanori Aikawa</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cellular Heterogeneity of Activated Primary Human Macrophages and Associated Drug-Gene Networks: From Biology to Precision Therapeutics</dc:title>
<dc:identifier>pmid:37850387</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064794</dc:identifier>
</item>
<item>
<title>Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850383/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Among patients with cardiogenic shock undergoing VA-ECMO, early routine left ventricular unloading with transseptal left atrial cannulation did not reduce 30-day mortality compared with the conventional strategy, which permitted rescue transseptal left atrial cannulation. These findings should be cautiously interpreted until the results of multicenter trials using other unloading modalities become available.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.123.066179. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although venoarterial extracorporeal membrane oxygenation (VA-ECMO) is beneficial for the treatment of profound cardiogenic shock, peripheral VA-ECMO cannulation can increase left ventricular afterload, thus compromising myocardial recovery. We investigated whether early routine left ventricular unloading can reduce 30-day mortality compared with the conventional approach in patients with cardiogenic shock undergoing VA-ECMO.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This randomized clinical trial involved 116 patients with cardiogenic shock undergoing VA-ECMO from March 2021 to September 2022 at Chonnam National University Hospital, Gwangju, South Korea. The patients were randomly assigned to undergo either early routine left ventricular unloading with transseptal left atrial cannulation within 12 hours after randomization (n=58) or the conventional approach, which permitted rescue transseptal left atrial cannulation in case of an increased left ventricular afterload (n=58). The primary outcome was all-cause mortality within 30 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: All 116 randomized patients (mean age, 67.6±13.5 years; 34 [29.3%] women) completed the trial. At 30 days, all-cause death had occurred in 27 (46.6%) patients in the early group and 26 (44.8%) patients in the conventional group (hazard ratio, 1.02 [95% CI, 0.59-1.74]; <i>P</i>=0.942). Crossover to rescue transseptal left atrial cannulation occurred in 29 patients (50%) in the conventional group according to a clear indication. Time to rescue transseptal cannulation in the conventional group was a median of 21.8 (interquartile range, 12.4-52.2) hours after randomization. There were no significant differences in other secondary outcomes between the 2 groups except for a shorter time to disappearance of pulmonary congestion in the early group (median, 3 [interquartile range, 2-6] versus 5 [interquartile range, 3-7] days; <i>P</i>=0.027).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with cardiogenic shock undergoing VA-ECMO, early routine left ventricular unloading with transseptal left atrial cannulation did not reduce 30-day mortality compared with the conventional strategy, which permitted rescue transseptal left atrial cannulation. These findings should be cautiously interpreted until the results of multicenter trials using other unloading modalities become available.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT04775472.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850383/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850383</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066179>10.1161/CIRCULATIONAHA.123.066179</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850383</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Min Chul Kim</dc:creator>
<dc:creator>Yongwhan Lim</dc:creator>
<dc:creator>Seung Hun Lee</dc:creator>
<dc:creator>Yoonmin Shin</dc:creator>
<dc:creator>Joon Ho Ahn</dc:creator>
<dc:creator>Dae Young Hyun</dc:creator>
<dc:creator>Kyung Hoon Cho</dc:creator>
<dc:creator>Doo Sun Sim</dc:creator>
<dc:creator>Young Joon Hong</dc:creator>
<dc:creator>Ju Han Kim</dc:creator>
<dc:creator>Myung Ho Jeong</dc:creator>
<dc:creator>Yong Hun Jung</dc:creator>
<dc:creator>In-Seok Jeong</dc:creator>
<dc:creator>Youngkeun Ahn</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37850383</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066179</dc:identifier>
</item>
<item>
<title>Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Inclisiran treatment did not reduce LDL-C levels in patients with homozygous familial hypercholesterolemia despite substantial lowering of PCSK9 levels. Inclisiran was well-tolerated, and the safety findings were consistent with previously reported studies and the overall safety profile.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Homozygous familial hypercholesterolemia is a genetic disease characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature cardiovascular events. Phase 2 of ORION (A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia) showed that inclisiran, a small interfering RNA that prevents production of the hepatic PCSK9 protein (proprotein convertase subtilisin/kexin type 9), could lead to durable reductions in LDL-C levels when added to statins and ezetimibe in patients with homozygous familial hypercholesterolemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: ORION-5 was a phase 3, 2-part, multicenter study in 56 patients with homozygous familial hypercholesterolemia and elevated LDL-C levels despite maximum tolerated doses of LDL-C-lowering therapies with or without lipoprotein apheresis. Patients eligible for part 1 (double-blind, 6 months) were randomized 2:1 to receive either 300 mg of inclisiran sodium (equivalent to 284 mg of inclisiran) or placebo. Placebo-treated patients from part 1 were transitioned to inclisiran in part 2 (open-label, 18 months). The primary end point was the percentage change in LDL-C levels from baseline to day 150.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean age of the patients was 42.7 years, and 60.7% were women. The mean baseline LDL-C levels were 294.0 mg/dL and 356.7 mg/dL in the inclisiran and placebo groups, respectively. The placebo-corrected percentage change in LDL-C level from baseline to day 150 was -1.68% (95% CI, -29.19% to 25.83%; <i>P</i>=0.90), and the difference was not statistically significant between the inclisiran and placebo groups. The placebo-corrected percentage change in PCSK9 levels from baseline to day 150 was -60.6% with inclisiran treatment (<i>P</i>&lt;0.0001); this was sustained throughout the study, confirming the effect of inclisiran on its biological target of PCSK9. No statistically significant differences between the inclisiran and placebo groups were observed in the levels of other lipids and lipoproteins (apolipoprotein B, total cholesterol, and non-high-density lipoprotein cholesterol). Adverse events and serious adverse events did not differ between the inclisiran and placebo groups throughout the study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Inclisiran treatment did not reduce LDL-C levels in patients with homozygous familial hypercholesterolemia despite substantial lowering of PCSK9 levels. Inclisiran was well-tolerated, and the safety findings were consistent with previously reported studies and the overall safety profile.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT03851705.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850379</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063460>10.1161/CIRCULATIONAHA.122.063460</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850379</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Frederick Raal</dc:creator>
<dc:creator>Ronen Durst</dc:creator>
<dc:creator>Ran Bi</dc:creator>
<dc:creator>Zsolt Talloczy</dc:creator>
<dc:creator>Pierre Maheux</dc:creator>
<dc:creator>Anastasia Lesogor</dc:creator>
<dc:creator>John J P Kastelein</dc:creator>
<dc:creator>ORION-5 Study Investigators</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37850379</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063460</dc:identifier>
</item>
<item>
<title>Role of cAMP in Cardiomyocyte Viability: Beneficial or Detrimental?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37850368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our findings indicate that the functional diversity of different GsPCRs in cardiomyocyte viability could be achieved by their ability to form unique signaling complexes (signalosomes) that determine the fate of cAMP: either stimulate ATP release by activating PKA or directly efflux to be e[cAMP].</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 18. doi: 10.1161/CIRCRESAHA.123.322652. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: 3', 5'-cyclic AMP (cAMP) regulates numerous cardiac functions. Various hormones and neurotransmitters elevate intracellular cAMP (i[cAMP]) in cardiomyocytes through activating stimulatory GsPCRs (G protein [Gs]-coupled receptors) and membrane-bound ACs (adenylyl cyclases). Increasing evidence has indicated that stimulating different GsPCRs and ACs exhibits distinct, even opposite effects, on cardiomyocyte viability. However, the underlying mechanisms are not fully understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used molecular and pharmacological approaches to investigate how different GsPCR/cAMP signaling differentially regulate cardiomyocyte viability with in vitro, ex vivo, and in vivo models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: For prodeath GsPCRs, we explored beta1-adrenergic-receptor and histamine-H2-receptor. We found that their prodeath effects were similarly dependent on AC5 activation, ATP release to the extracellular space via PANX1 (pannexin-1) channel, and extracellular ATP (e[ATP])-mediated signaling involving in P2X7R (P2X purinoceptor 7) and CaMKII (Ca<sup>2+</sup>/calmodulin-dependent protein kinase II). PANX1 phosphorylation at Serine 206 by cAMP-dependent-PKA (protein-kinase-A) promoted PANX1 activation, which was critical in beta1-adrenergic-receptor- or histamine-H2-receptor-induced cardiomyocyte death in vitro and in vivo. Beta1-adrenergic-receptor or histamine-H2-receptor was localized proximately to PANX1, which permits ATP release. For prosurvival GsPCRs, we explored adenosine-A2-receptor (A2R), calcitonin-gene-related-peptide-receptor, and RXFP1 (relaxin-family peptide-receptor 1). Their prosurvival effects were dependent on AC6 activation, cAMP efflux via MRP4 (multidrug resistance protein 4), extracellular cAMP metabolism to adenosine (e[cAMP]-to-e[ADO]), and e[ADO]-mediated signaling. A2R, calcitonin-gene-related-peptide-receptor, or RXFP1 was localized proximately to MRP4, which enables cAMP efflux. Interestingly, exogenously increasing e[cAMP] levels by membrane-impermeable cAMP protected against cardiomyocyte death in vitro and in ex vivo and in vivo mouse hearts with ischemia-reperfusion injuries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings indicate that the functional diversity of different GsPCRs in cardiomyocyte viability could be achieved by their ability to form unique signaling complexes (signalosomes) that determine the fate of cAMP: either stimulate ATP release by activating PKA or directly efflux to be e[cAMP].</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37850368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37850368</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322652>10.1161/CIRCRESAHA.123.322652</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37850368</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Yishuai Zhang</dc:creator>
<dc:creator>Si Chen</dc:creator>
<dc:creator>Lingfeng Luo</dc:creator>
<dc:creator>Sarah Greenly</dc:creator>
<dc:creator>Hangchuan Shi</dc:creator>
<dc:creator>Jasmine Jiayuan Xu</dc:creator>
<dc:creator>Chen Yan</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Role of cAMP in Cardiomyocyte Viability: Beneficial or Detrimental?</dc:title>
<dc:identifier>pmid:37850368</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322652</dc:identifier>
</item>
<item>
<title>Oxidized phospholipids in cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37848630/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>Prolonged or excessive exposure to oxidized phospholipids (OxPLs) generates chronic inflammation. OxPLs are present in atherosclerotic lesions and can be detected in plasma on apolipoprotein B (apoB)-containing lipoproteins. When initially conceptualized, OxPL-apoB measurement in plasma was expected to reflect the concentration of minimally oxidized LDL, but, surprisingly, it correlated more strongly with plasma lipoprotein(a) (Lp(a)) levels. Indeed, experimental and clinical studies show that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 17. doi: 10.1038/s41569-023-00937-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Prolonged or excessive exposure to oxidized phospholipids (OxPLs) generates chronic inflammation. OxPLs are present in atherosclerotic lesions and can be detected in plasma on apolipoprotein B (apoB)-containing lipoproteins. When initially conceptualized, OxPL-apoB measurement in plasma was expected to reflect the concentration of minimally oxidized LDL, but, surprisingly, it correlated more strongly with plasma lipoprotein(a) (Lp(a)) levels. Indeed, experimental and clinical studies show that Lp(a) particles carry the largest fraction of OxPLs among apoB-containing lipoproteins. Plasma OxPL-apoB levels provide diagnostic information on the presence and extent of atherosclerosis and improve the prognostication of peripheral artery disease and first and recurrent myocardial infarction and stroke. The addition of OxPL-apoB measurements to traditional cardiovascular risk factors improves risk reclassification, particularly in patients in intermediate risk categories, for whom improving decision-making is most impactful. Moreover, plasma OxPL-apoB levels predict cardiovascular events with similar or greater accuracy than plasma Lp(a) levels, probably because this measurement reflects both the genetics of elevated Lp(a) levels and the generalized or localized oxidation that modifies apoB-containing lipoproteins and leads to inflammation. Plasma OxPL-apoB levels are reduced by Lp(a)-lowering therapy with antisense oligonucleotides and by lipoprotein apheresis, niacin therapy and bariatric surgery. In this Review, we discuss the role of role OxPLs in the pathophysiology of atherosclerosis and Lp(a) atherogenicity, and the use of OxPL-apoB measurement for improving prognosis, risk reclassification and therapeutic interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37848630/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37848630</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00937-4>10.1038/s41569-023-00937-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37848630</guid>
<pubDate>Tue, 17 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:creator>Joseph L Witztum</dc:creator>
<dc:date>2023-10-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Oxidized phospholipids in cardiovascular disease</dc:title>
<dc:identifier>pmid:37848630</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00937-4</dc:identifier>
</item>
<item>
<title>Depolarization of fibroblasts in scar tissue drives cardiac excitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37848629/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 17. doi: 10.1038/s41569-023-00948-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37848629/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37848629</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00948-1>10.1038/s41569-023-00948-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37848629</guid>
<pubDate>Tue, 17 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-10-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Depolarization of fibroblasts in scar tissue drives cardiac excitation</dc:title>
<dc:identifier>pmid:37848629</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00948-1</dc:identifier>
</item>
<item>
<title>Serotonin reduction in post-acute sequelae of viral infection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37848036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>Post-acute sequelae of COVID-19 (PASC, "Long COVID") pose a significant global health challenge. The pathophysiology is unknown, and no effective treatments have been found to date. Several hypotheses have been formulated to explain the etiology of PASC, including viral persistence, chronic inflammation, hypercoagulability, and autonomic dysfunction. Here, we propose a mechanism that links all four hypotheses in a single pathway and provides actionable insights for therapeutic interventions. We...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 9:S0092-8674(23)01034-6. doi: 10.1016/j.cell.2023.09.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Post-acute sequelae of COVID-19 (PASC, "Long COVID") pose a significant global health challenge. The pathophysiology is unknown, and no effective treatments have been found to date. Several hypotheses have been formulated to explain the etiology of PASC, including viral persistence, chronic inflammation, hypercoagulability, and autonomic dysfunction. Here, we propose a mechanism that links all four hypotheses in a single pathway and provides actionable insights for therapeutic interventions. We find that PASC are associated with serotonin reduction. Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover. Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory. These findings provide a possible explanation for neurocognitive symptoms associated with viral persistence in Long COVID, which may extend to other post-viral syndromes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37848036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37848036</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.013>10.1016/j.cell.2023.09.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37848036</guid>
<pubDate>Tue, 17 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrea C Wong</dc:creator>
<dc:creator>Ashwarya S Devason</dc:creator>
<dc:creator>Iboro C Umana</dc:creator>
<dc:creator>Timothy O Cox</dc:creator>
<dc:creator>Lenka Dohnalová</dc:creator>
<dc:creator>Lev Litichevskiy</dc:creator>
<dc:creator>Jonathan Perla</dc:creator>
<dc:creator>Patrick Lundgren</dc:creator>
<dc:creator>Zienab Etwebi</dc:creator>
<dc:creator>Luke T Izzo</dc:creator>
<dc:creator>Jihee Kim</dc:creator>
<dc:creator>Monika Tetlak</dc:creator>
<dc:creator>Hélène C Descamps</dc:creator>
<dc:creator>Simone L Park</dc:creator>
<dc:creator>Stephen Wisser</dc:creator>
<dc:creator>Aaron D McKnight</dc:creator>
<dc:creator>Ryan D Pardy</dc:creator>
<dc:creator>Junwon Kim</dc:creator>
<dc:creator>Niklas Blank</dc:creator>
<dc:creator>Shaan Patel</dc:creator>
<dc:creator>Katharina Thum</dc:creator>
<dc:creator>Sydney Mason</dc:creator>
<dc:creator>Jean-Christophe Beltra</dc:creator>
<dc:creator>Michaël F Michieletto</dc:creator>
<dc:creator>Shin Foong Ngiow</dc:creator>
<dc:creator>Brittany M Miller</dc:creator>
<dc:creator>Megan J Liou</dc:creator>
<dc:creator>Bhoomi Madhu</dc:creator>
<dc:creator>Oxana Dmitrieva-Posocco</dc:creator>
<dc:creator>Alex S Huber</dc:creator>
<dc:creator>Peter Hewins</dc:creator>
<dc:creator>Christopher Petucci</dc:creator>
<dc:creator>Candice P Chu</dc:creator>
<dc:creator>Gwen Baraniecki-Zwil</dc:creator>
<dc:creator>Leila B Giron</dc:creator>
<dc:creator>Amy E Baxter</dc:creator>
<dc:creator>Allison R Greenplate</dc:creator>
<dc:creator>Charlotte Kearns</dc:creator>
<dc:creator>Kathleen Montone</dc:creator>
<dc:creator>Leslie A Litzky</dc:creator>
<dc:creator>Michael Feldman</dc:creator>
<dc:creator>Jorge Henao-Mejia</dc:creator>
<dc:creator>Boris Striepen</dc:creator>
<dc:creator>Holly Ramage</dc:creator>
<dc:creator>Kellie A Jurado</dc:creator>
<dc:creator>Kathryn E Wellen</dc:creator>
<dc:creator>Una O'Doherty</dc:creator>
<dc:creator>Mohamed Abdel-Mohsen</dc:creator>
<dc:creator>Alan L Landay</dc:creator>
<dc:creator>Ali Keshavarzian</dc:creator>
<dc:creator>Timothy J Henrich</dc:creator>
<dc:creator>Steven G Deeks</dc:creator>
<dc:creator>Michael J Peluso</dc:creator>
<dc:creator>Nuala J Meyer</dc:creator>
<dc:creator>E John Wherry</dc:creator>
<dc:creator>Benjamin A Abramoff</dc:creator>
<dc:creator>Sara Cherry</dc:creator>
<dc:creator>Christoph A Thaiss</dc:creator>
<dc:creator>Maayan Levy</dc:creator>
<dc:date>2023-10-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Serotonin reduction in post-acute sequelae of viral infection</dc:title>
<dc:identifier>pmid:37848036</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.013</dc:identifier>
</item>
<item>
<title>Accelerating Alzheimer's therapeutic development: The past and future of clinical trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37848035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231018203714&amp;v=2.17.9.post6+86293ac
      <description>Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years to achieve these successes? Developing potent therapies for reducing fibrillar amyloid was key, as was selection of patients at relatively early stages of disease. Biomarkers of the target pathologies, including amyloid and tau PET, and insights from past trials were also critical to the recent successes. Moving...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 13:S0092-8674(23)01077-2. doi: 10.1016/j.cell.2023.09.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years to achieve these successes? Developing potent therapies for reducing fibrillar amyloid was key, as was selection of patients at relatively early stages of disease. Biomarkers of the target pathologies, including amyloid and tau PET, and insights from past trials were also critical to the recent successes. Moving forward, the challenge will be to develop more efficacious therapies with greater efficiency. Novel trial designs, including combination therapies and umbrella and basket protocols, will accelerate clinical development. Better diversity and inclusivity of trial participants are needed, and blood-based biomarkers may help to improve access for medically underserved groups. Incentivizing innovation in both academia and industry through public-private partnerships, collaborative mechanisms, and the creation of new career paths will be critical to build momentum in these exciting times.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37848035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231018203714&v=2.17.9.post6+86293ac">37848035</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.023>10.1016/j.cell.2023.09.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37848035</guid>
<pubDate>Tue, 17 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Adam L Boxer</dc:creator>
<dc:creator>Reisa Sperling</dc:creator>
<dc:date>2023-10-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Accelerating Alzheimer's therapeutic development: The past and future of clinical trials</dc:title>
<dc:identifier>pmid:37848035</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.023</dc:identifier>
</item>





























</channel>
</rss>